Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Bio-Path stock | $3.86

Own Bio-Path stock in just a few minutes.

Fact checked

Bio-Path Holdings, Inc is a biotechnology business based in the US. Bio-Path shares (BPTH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Path employs 9 staff and has a market cap (total outstanding shares value) of USD$17.3 million.

How to buy shares in Bio-Path

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Bio-Path. Find the stock by name or ticker symbol: BPTH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Bio-Path reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$3.86, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Bio-Path, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Bio-Path. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Bio-Path share price

Use our graph to track the performance of BPTH stocks over time.

Bio-Path shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$3.86
52-week rangeUSD$2.9203 - USD$8.49
50-day moving average USD$3.5706
200-day moving average USD$4.3435
Wall St. target priceUSD$10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-6.191

Buy Bio-Path shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Bio-Path stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bio-Path price performance over time

Historical closes compared with the close of $3.86 from 2020-12-09

1 week (2021-01-12) -1.78%
1 month (2020-12-18) 4.32%
3 months (2020-10-19) -4.46%
6 months (2020-07-17) -29.69%
1 year (2020-01-17) -49.01%
2 years (2019-01-18) 120.57%
3 years (2018-01-19) 1,692.85%
5 years (2016-01-19) 188.06%

Bio-Path financials

Gross profit TTM USD$0
Return on assets TTM -41.46%
Return on equity TTM -73.41%
Profit margin 0%
Book value $3.572
Market capitalisation USD$17.3 million

TTM: trailing 12 months

Shorting Bio-Path shares

There are currently 241,751 Bio-Path shares held short by investors – that's known as Bio-Path's "short interest". This figure is 6.9% up from 226,126 last month.

There are a few different ways that this level of interest in shorting Bio-Path shares can be evaluated.

Bio-Path's "short interest ratio" (SIR)

Bio-Path's "short interest ratio" (SIR) is the quantity of Bio-Path shares currently shorted divided by the average quantity of Bio-Path shares traded daily (recently around 309937.17948718). Bio-Path's SIR currently stands at 0.78. In other words for every 100,000 Bio-Path shares traded daily on the market, roughly 780 shares are currently held short.

However Bio-Path's short interest can also be evaluated against the total number of Bio-Path shares, or, against the total number of tradable Bio-Path shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Bio-Path's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Bio-Path shares in existence, roughly 60 shares are currently held short) or 0.0593% of the tradable shares (for every 100,000 tradable Bio-Path shares, roughly 59 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Bio-Path.

Find out more about how you can short Bio-Path stock.

Bio-Path share dividends

We're not expecting Bio-Path to pay a dividend over the next 12 months.

Have Bio-Path's shares ever split?

Bio-Path's shares were split on a 1:20 basis on 18 January 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Bio-Path shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Bio-Path shares which in turn could have impacted Bio-Path's share price.

Bio-Path share price volatility

Over the last 12 months, Bio-Path's shares have ranged in value from as little as $2.9203 up to $8.49. A popular way to gauge a stock's volatility is its "beta".

BPTH.US volatility(beta: 2.1)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Path's is 2.0976. This would suggest that Bio-Path's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Bio-Path overview

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome; and in Phase IIa clinical trials for the treatment of chronic myeloid leukemia, as well as to treat solid tumors. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site